{
    "clinical_study": {
        "@rank": "146505", 
        "brief_summary": {
            "textblock": "To investigate the safety and tolerance of an increasing number of infusions per week of\n      alvircept sudotox ( sCD4-PE40; soluble CD4-Pseudomonas exotoxin ) at a fixed dose when\n      administered to HIV-1-infected individuals. To investigate the effect of sCD4-PE40 on the\n      following parameters: T lymphocyte subsets, plasma HIV RNA and cellular HIV proviral DNA in\n      PBMC and CD4 cells, p24 levels, serum beta-2 microglobulin, and neopterin levels."
        }, 
        "brief_title": "Safety, Tolerance, Efficacy and Pharmacokinetics of Multiple Doses of sCD4-PE40 in the Treatment of HIV-Infected Individuals", 
        "condition": "HIV Infections", 
        "condition_browse": {
            "mesh_term": [
                "HIV Infections", 
                "Acquired Immunodeficiency Syndrome"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n        Patients must have:\n\n          -  HIV positivity confirmed by Western blot.\n\n          -  CD4 count of 100 - 500 cells/mm3 on a morning draw within 3 weeks prior to study\n             entry.\n\n        Exclusion Criteria\n\n        Co-existing Condition:\n\n        Patients with the following symptoms and conditions are excluded:\n\n          -  Concurrent neoplasms other than basal cell carcinoma of the skin, in situ carcinoma\n             of the cervix, or nondisseminated Kaposi's sarcoma.\n\n          -  Hemophilia or other clotting disorders.\n\n          -  Major organ allograft.\n\n          -  Significant cardiac, hepatic, renal, or CNS disease.\n\n        Prior Medication:\n\n        Excluded:\n\n          -  Antiretroviral agents within 2 months prior to study entry.\n\n          -  Known anti-HIV medication within 60 days prior to study entry.\n\n          -  Prior immunomodulators (e.g., systemic steroids, interferons, or interleukins) or\n             other chemotherapy.\n\n        Prior Treatment:\n\n        Excluded:\n\n          -  Prior radiation therapy. Active substance abuse."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "firstreceived_date": "November 2, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00002087", 
            "org_study_id": "084A", 
            "secondary_id": [
                "Amend 022", 
                "P/3325/0002"
            ]
        }, 
        "intervention": {
            "intervention_name": "Alvircept sudotox", 
            "intervention_type": "Drug"
        }, 
        "keyword": [
            "Recombinant Proteins", 
            "Acquired Immunodeficiency Syndrome", 
            "Antigens, CD4", 
            "AIDS-Related Complex"
        ], 
        "lastchanged_date": "June 23, 2005", 
        "location": {
            "facility": {
                "address": {
                    "city": "Stanford", 
                    "country": "United States", 
                    "state": "California", 
                    "zip": "943055107"
                }, 
                "name": "Stanford Univ Med Ctr"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "Safety, Tolerance, Efficacy and Pharmacokinetics of Multiple Doses of sCD4-PE40 in the Treatment of HIV-Infected Individuals", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 1", 
        "reference": {
            "PMID": "7963711", 
            "citation": "Davey RT Jr, Boenning CM, Herpin BR, Batts DH, Metcalf JA, Wathen L, Cox SR, Polis MA, Kovacs JA, Falloon J, et al. Use of recombinant soluble CD4 Pseudomonas exotoxin, a novel immunotoxin, for treatment of persons infected with human immunodeficiency virus. J Infect Dis. 1994 Nov;170(5):1180-8."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00002087"
        }, 
        "source": "NIH AIDS Clinical Trials Information Service", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Pharmacia and Upjohn", 
                "agency_class": "Industry"
            }
        }, 
        "study_design": "Endpoint Classification: Pharmacokinetics Study, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 1994"
    }, 
    "geocoordinates": {
        "Stanford Univ Med Ctr": "37.429 -122.169"
    }
}